Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8+ dendritic cells

Department of Pathology and Department of Medicine, Section of Hematology/Oncology, the University of Chicago, Chicago, IL, USA.
Journal of Experimental Medicine (Impact Factor: 12.52). 09/2011; 208(10):2005-16. DOI: 10.1084/jem.20101159
Source: PubMed


Despite lack of tumor control in many models, spontaneous T cell priming occurs frequently in response to a growing tumor. However, the innate immune mechanisms that promote natural antitumor T cell responses are undefined. In human metastatic melanoma, there was a correlation between a type I interferon (IFN) transcriptional profile and T cell markers in metastatic tumor tissue. In mice, IFN-β was produced by CD11c(+) cells after tumor implantation, and tumor-induced T cell priming was defective in mice lacking IFN-α/βR or Stat1. IFN signaling was required in the hematopoietic compartment at the level of host antigen-presenting cells, and selectively for intratumoral accumulation of CD8α(+) dendritic cells, which were demonstrated to be essential using Batf3(-/-) mice. Thus, host type I IFNs are critical for the innate immune recognition of a growing tumor through signaling on CD8α(+) DCs.

Download full-text


Available from: Seng-Ryong Woo
    • "Cell-extrinsic functions of STAT1 likely contribute to the anti-tumour T cell activity . Type I IFNs, for example, promote the cross-presenting ability of CD8a + dendritic cells (DCs) to CD8 + T cells, which is required for CD8 + T cell priming and tumour rejection and depends on STAT1 [97] [98]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Signal transducer and activator of transcription (STAT) 1 is part of the Janus kinase (JAK)/STAT signalling cascade and is best known for its essential role in mediating responses to all types of interferons (IFN). STAT1 regulates a variety of cellular processes, such as antimicrobial activities, cell proliferation and cell death. It exerts important immune modulatory activities both in the innate and the adaptive arm of the immune system. Based on studies in mice and data from human patients, STAT1 is generally considered a tumour suppressor but there is growing evidence that it can also act as a tumour promoter. This review aims at contrasting the two faces of STAT1 in tumourigenesis and providing an overview on the current knowledge of the underlying mechanisms or pathways.
    No preview · Article · Nov 2015 · Cytokine
  • Source
    • "Over the past few decades, the GC prognosis continues to be poor, with 5-year survival rates of approximately 20% [1] [4]. The reasons for metastasis and recurrence of GC can be summarized as following: (I) The intrinsic antigenicity weakness of tumor cells [5] [6], immunological surveillance of the host can not identify and eliminate the malignant cells that distributed out of the resection field and the peripheral lymphoid organs. (II) Immunological surveillance defect or dysfunction of the host. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dendritic cells (DCs) have displayed the promising potential in cancer immunity. How to enhance DCs immunotherapeutic effect in cancer targeted immunotherapy and prevention is still a great challenge. Herein, we report for the first time the allogenic DCs and tumor cell fused vaccine combined with cytokine induced killing cells (CIKs) for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer (GC). The fused vaccine was prepared by PEG mediated fusion between mature DCs and inactive gastric cancer MGC803 cells. The immunotherapeutic and prophylactic potential of the fused cells (FCs) were evaluated in tumor-bearing, post-surgery and tumor free mice models. The migration and homing process of near infrared region quantum dots (NIR-QDs) labeled FCs were investigated by real-time animal imaging system. Results showed that the FCs and FC þ CIKs could trigger the tumorspecific CTLs against GC cells, target the tumor tissue initiatively and enhance the prophylactic effects, suppress the tumor growth remarkably in vivo. The potential mechanism is also investigated. In conclusion, allogenic DCs and tumor cell fused vaccine can be used for targeted imaging and enhanced immunotherapeutic efficacy of GC, and the FC þ CIKs strategy own great potential in clinical applications such as early therapy and prevention of tumor-metastasis and relapse in near future.
    Full-text · Dataset · Oct 2015
  • Source
    • "- tumor immune effector pathways , including those controlled by type I IFNs . COX Expression in Braf V600E Cells Prevents CD103 + DC Accumulation and Activation in Tumors DCs , especially the Batf3 - dependent sub - family characterized by CD8a and / or CD103 expression , are essential for anti - cancer immune responses ( Diamond et al . , 2011 ; Fuertes et al . , 2011 ; Hildner et al . , 2008 ) . We therefore assessed the impact of tumor - specific COX ablation on the prevalence and activation status of DCs at the tumor site , focusing on the CD103 + subset . Despite being only a minority of DCs , CD103 + DCs were selec - tively absent from COX - competent tumors ( Figure 3A ) . More - over , the fra"
    [Show abstract] [Hide abstract]
    ABSTRACT: The mechanisms by which melanoma and other cancer cells evade anti-tumor immunity remain incompletely understood. Here, we show that the growth of tumors formed by mutant Braf(V600E) mouse melanoma cells in an immunocompetent host requires their production of prostaglandin E2, which suppresses immunity and fuels tumor-promoting inflammation. Genetic ablation of cyclooxygenases (COX) or prostaglandin E synthases in Braf(V600E) mouse melanoma cells, as well as in Nras(G12D) melanoma or in breast or colorectal cancer cells, renders them susceptible to immune control and provokes a shift in the tumor inflammatory profile toward classic anti-cancer immune pathways. This mouse COX-dependent inflammatory signature is remarkably conserved in human cutaneous melanoma biopsies, arguing for COX activity as a driver of immune suppression across species. Pre-clinical data demonstrate that inhibition of COX synergizes with anti-PD-1 blockade in inducing eradication of tumors, implying that COX inhibitors could be useful adjuvants for immune-based therapies in cancer patients.
    Full-text · Article · Sep 2015 · Cell
Show more